Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a digital guide empower women in polluted communities to make informed mammogram choices?

NCT ID NCT06098118

Knowledge-focused Sponsor: Trustees of Dartmouth College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This study tests an adapted online decision aid, called MyMammogram, designed to help women aged 39-49 who live in communities with PFAS contamination make informed choices about breast cancer screening. The tool provides personalized risk assessment, information on mammography benefits and risks, and helps clarify personal values. The goal is to see if the aid is acceptable and improves knowledge and decision-making about screening in a population with heightened environmental concerns.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MyMammogram decision aid (an online breast cancer screening decision aid)
What this could lead to
If successful, this could provide a tailored tool to help women in PFAS-contaminated communities make informed breast cancer screening decisions, potentially reducing anxiety and improving decision quality.
What could go wrong
This is a small, early-stage study focused on decision-making, not on health outcomes. The decision aid may not change actual screening behavior or may not be generalizable to other communities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

May 2024

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

39 to 49 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Females aged 39-49 * No personal history of breast cancer, * No mammogram in the prior 12 months * Resident of Merrimack, Hillsborough, Rockingham or Bennington counties Exclusion Criteria: * History of breast cancer, ductal carcinoma in situ, lobular carcinoma in situ * Cognitive impairment impeding the ability to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer screening are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Progressive Encephalomyelitis with Rigidity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer screening

Contacts and locations

Locations

  • Dartmouth College

    Hanover, New Hampshire, 03755, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.